Lymphoma & CLL Therapeutics

Safety and efficacy of oral azacitidine (CC-486) plus R-CHOP in patients with previously untreated intermediate- to high-risk DLBCL: A phase I study

The combination of rituximab and cyclophosphamide,...

AACR 2020 | Preliminary results of the EMBOLDEN and DURABILITY phase I studies on the combination of immune checkpoint inhibitors with epigenetic therapy in patients with T-cell lymphoma

At the...

Loncastuximab tesirine granted orphan drug designation in the European Union for the treatment of patients with DLBCL

On September 13, 2021, the European Commission (EC) granted orphan drug...

Brentuximab vedotin in combination with standard chemotherapy for pediatric patients with newly diagnosed, ALK+ ALCL

Anaplastic large-cell lymphoma (ALCL) is a type of non-Hodgkin lymphoma that...

Clonal hematopoiesis and CAR T-cell therapy outcomes

Clonal hematopoiesis (CH) is defined as the clonal expansion of hematopoietic stem cells, resulting in blood cells with the same genetic mutations....

How do we select a patient with R/R DLBCL for CAR-T?

During the European School of Haematology (ESH) How I manage CAR-T Therapies and Bispecific Antibodies for my Patients conference, the Lymphoma Hub...

Zanubrutinib granted accelerated approval by the FDA for the treatment of patients with R/R MZL

On September 15, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to...

DZD4205, an oral JAK inhibitor for the treatment of R/R PTCL: JACKPOT8 phase I trial results

Relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL) is an aggressive and rare type of...